Evolving strategies in the treatment of anaemia in chronic kidney disease: the HIF-prolyl hydroxylase inhibitors
F Locatelli, R Minutolo, L De Nicola, L Del Vecchio - Drugs, 2022 - Springer
… Hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD) inhibitors (HIF-PHIs) were
… Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors may also have additional …
… Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors may also have additional …
Pharmacological targeting of the HIF hydroxylases–a new field in medicine development
MC Chan, JP Holt-Martyn, CJ Schofield… - Molecular aspects of …, 2016 - Elsevier
… inhibitor design. … HIF hydroxylases and possible modes of inhibition To place studies on
the therapeutic modulation of the HIF hydroxylases (including the potential for specific inhibition) …
the therapeutic modulation of the HIF hydroxylases (including the potential for specific inhibition) …
P450-catalyzed regio-and diastereoselective steroid hydroxylation: efficient directed evolution enabled by mutability landscaping
… how optimally chosen directed evolution techniques can be … mutants for efficient steroid
hydroxylation at the specifically targeted … variants were evolved that catalyze the hydroxylation of …
hydroxylation at the specifically targeted … variants were evolved that catalyze the hydroxylation of …
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
PH Maxwell, KU Eckardt - Nature Reviews Nephrology, 2016 - nature.com
… This inhibition was initially demonstrated with dimethyloxalylglycine, a cell-… inhibitor that
reduces HIF hydroxylation 54 . A substantial number of small-molecule PHD enzyme inhibitors …
reduces HIF hydroxylation 54 . A substantial number of small-molecule PHD enzyme inhibitors …
The evolution of cytochrome P450 enzymes as biocatalysts in drug discovery and development
E MJ Gillam, MA Hayes - Current topics in medicinal chemistry, 2013 - ingentaconnect.com
… Indeed much of our theoretical and practical understanding of directed evolution strategies
has been built on or exemplified by engineering of P450 BM3 [123-129]. While both P450 …
has been built on or exemplified by engineering of P450 BM3 [123-129]. While both P450 …
CYP17-and CYP11B-dependent steroid hydroxylases as drug development targets
T Hakki, R Bernhardt - Pharmacology & therapeutics, 2006 - Elsevier
… hydroxylases are not yet available, computer models of the corresponding CYPs may help to
develop new inhibitors … gene (CYP11B2), which has evolved by duplication of CYP11B1 to …
develop new inhibitors … gene (CYP11B2), which has evolved by duplication of CYP11B1 to …
Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics?
SS Karuppagounder, RR Ratan - Journal of Cerebral Blood …, 2012 - journals.sagepub.com
… Schematic representation reflects the evolution in our thinking regarding the mechanisms
of neuroprotection by iron chelators. In the old model, deferoxamine (DFO) activates adaptive …
of neuroprotection by iron chelators. In the old model, deferoxamine (DFO) activates adaptive …
The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans
PB Danielson - Current drug metabolism, 2002 - ingentaconnect.com
… enzymes and one which likely evolved as an extension of the … 25hydroxylation and 25-hydroxy-D3
1α-hydroxylation, and … -D3 24-hydroxylation and 1α,25-dihydroxy 24hydroxylation. …
1α-hydroxylation, and … -D3 24-hydroxylation and 1α,25-dihydroxy 24hydroxylation. …
Hypoxia inducible factor stabilization as a novel strategy to treat anemia
S Zhao, J Wu - Current medicinal chemistry, 2013 - ingentaconnect.com
… Development and evolution of animals largely rely on harness of the oxidizing potential of
… L-Mimosine has also been reported to act as a prolyl 4-hydroxylase inhibitor and has similar …
… L-Mimosine has also been reported to act as a prolyl 4-hydroxylase inhibitor and has similar …
Prolyl hydroxylase inhibitors act as agents to enhance the efficiency of cell therapy
… hydroxylase (PHD) inhibitors are considered as promising solutions for stem cell-based
therapy. PHD inhibitors … , HIF-1 and especially PHD inhibitors on cell therapy. PHD structure and …
therapy. PHD inhibitors … , HIF-1 and especially PHD inhibitors on cell therapy. PHD structure and …
相关搜索
- factor prolyl hydroxylase inhibitors
- hif prolyl hydroxylase inhibitors
- hydroxylase inhibitors hypoxia inducible factors
- treatment of anemia prolyl hydroxylase inhibitors
- cell therapy prolyl hydroxylase inhibitors
- comprehensive review prolyl hydroxylase inhibitors
- hydroxylase inhibitors chronic kidney disease
- evolving strategies in the treatment
- hydroxylase inhibitors anemia management
- hydroxylase inhibitors renal anemia
- hydroxylase inhibitors patients with ckd
- hydroxylase inhibitors clinical potential
- hydroxylase inhibitors advantages and disadvantages
- hydroxylase inhibitors randomized controlled trials